A new chapter for vascular surgery procedures will be introduced to the Swedish Classification of Health Care Measures from January 2021

Dec 2020

In early December 2020, the Swedish National Board of Health and Welfare announced significant changes in the Swedish Classification of Health Care Measures (KVÅ) structure related to vascular surgery procedure codes.

KVÅ includes two parts – medical procedures (KMÅ) and surgical procedures (KKÅ) divided by chapters based on anatomical principles. Currently, vascular surgical procedures are coded under several chapters:

KKÅ chapter P “Operations on peripheral vessels and the lymphatic system”
KKÅ chapter F “Operations on the heart and large intrathoracic vessels”
KKÅ chapter T “Minor surgery on peripheral vessels and lymphatic system”
KMÅ chapter DP “Peripheral vessels and lymphatic system”

From January 01, 2021, Chapter P will be fully deleted and replaced by new Chapter V, “Operations on the aorta, peripheral vessels and lymphatic system”, which includes all vascular surgical procedures, and covers the entire artery tree from the ascending aorta after the coronary arteries' departures.

Codes from Chapter F related to thoracic and thoracoabdominal aorta surgery, code TPH10 “Sclerosing of bone varices”, and codes DP007-DP016 will be replaced by new codes under Chapter V.

Lists of new Chapter V codes and mapping from other chapters, in MS Excel format tables, are published on December 01, 2020.

See more information in Swedish here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

MTP Council updated recommendations on gene expression analysis for decision-making on the adjuvant breast cancer treatment

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

2022 RIHN and Supplementary list for IVD tests published in France

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Swedish MTP Council updated the recommendations on FreeStyle Libre

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

New procedure and diagnostic codes added to the private reimbursement schedule in England

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Assessments of monitoring and diagnostics of atrial fibrillation products released in Sweden

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.